Genmab

	5/2 18:41 af JørgenVarnæs	only if you leverage your down-payment heavily
	5/2 18:40 af E L	and hopefully it won't be a second hand, 20 year old Subaru ;)
	5/2 18:40 af JørgenVarnæs	absolutely, I know my bias is very negative at the moment. However, Jan waving KYSO in our faces and delivering next to nothing to stockholders, is hard to watch
	5/2 18:39 af E L	looking forward to the day someone starts to talk about the make of his new car again here ;-)
	5/2 18:38 af E L	yes, that looks rather shitty today... hence the bad mood here sometimes ... and the mood drives the price again , it is a nasty circle...
	5/2 18:30 af JørgenVarnæs	speaking of track record - GEN has a compounded RoI of 9% since IPO
	5/2 18:29 af JørgenVarnæs	Something does not add up
	5/2 18:28 af JørgenVarnæs	As I recall, GEN had a stock emission first time the stock hit 1000 and diluted investors by 10%. That was almost 10 years ago and the rationale was to bolster the coffers and secure funds for investments. We've heard that song ever since, but investments have been precious few
	5/2 18:26 af E L	i also would like to see something done with their newer tech, like hexelect
	5/2 18:26 af ProInvestorNEWS	Novo lægger mere end en Genmab til markedsværdien efter opkøb (link)
	5/2 18:25 af E L	don't get me wrong, i am also impatient and would love to see more, but i do still like their track record, albeit some with the help of JNJ
	5/2 18:23 af E L	we both remember the time they had to fire staff, long time ago...
	5/2 18:23 af E L	and they have been able to hire the staff to do that
	5/2 18:22 af E L	but you have to be fair in that only the last few years they have been able to spend real money based on Dara earnings...
	5/2 18:21 af JørgenVarnæs	again, indeed you need early stage clinical trials for that - but this is a company going on it's 24rd year, promising breakthrough R&D. And we are still only talking about 1st generation mabs.
	5/2 18:20 af E L	let alone HuMax-IL8 or MAGIC-8 by BMS, when is the lat time we heard anything from them, i think they almost have 10 trials in clinic with that ab
	5/2 18:19 af E L	look at how long it takes for Lundbeck's Lu AF82422 of Novo's mim8...
	5/2 18:18 af E L	and to start a Ph3 you really need to think you have a winner, i know everyone thinks they have too much money, but they are very costly...
	5/2 18:16 af E L	you need ph1 and 2 first JV, you can't skip a stage unfortunately...
	5/2 18:16 af E L	i their defence, the epco approval was record speed
	5/2 18:16 af JørgenVarnæs	but perhaps worse - there is a profound lack of phase 3 programs in the pipeline
	5/2 18:15 af E L	well we are waiting for GEN1042 /46 data, these are overdue, like HexaCD38 seem all a bit delayed. Not sure if that is due to covid
	5/2 18:15 af Raun	Tak for din vurdering @Solsen :-)
	5/2 18:15 af JørgenVarnæs	So far we've seen nothing from the Biontech collab but vailed hints about synergistic effect. I can't point to a single thing in the pipeline with the potential to break through

	5/2 18:13 af JørgenVarnæs	EL, indeed. But where are all the other programs showing clinical promise?
	5/2 18:12 af E L	that is not something you hope for in advance offcourse, ideally these would have gone further allready
	5/2 18:11 af E L	they stopped a few programs, eg HexaBody-DR5/DR5 , DuoHexabody-CD37, DuoBody-CD3x5T4 ,
	5/2 18:10 af E L	JV, epco was 50/50 after initial development
	5/2 18:09 af E L	but we haven't seen anything with Abbvie really besides epco
	5/2 18:09 af E L	on ADC; to be honest, i had expected something from their collaboration with Abbvie there, Jan was very enthusiastic at the time on Abbvie's ADC technology
	5/2 18:07 af JørgenVarnæs	how is KYSO the same as the need to enter 50/50 partnerships to get something off the ground?
	5/2 18:05 af Sukkeralf	Thats a good thing I think - different targets needs different tech
	5/2 18:05 af JørgenVarnæs	Apart from hexa - when was the last time we saw results from the clinic on new programs?
	5/2 18:04 af Sukkeralf	If Genmab want and ADC for instance they need to partner up with a ADC company like everyone else
	5/2 18:02 af JørgenVarnæs	But it's really not that hard - once you have run the safety/dose escalation part of the clinical development, you are in a very different place negotiation-wise. GEN has done very little of this. In fact, it seems they need to partner with other companies to have the necessary tech to even get programs into the clinic
	5/2 17:59 af E L	the 50/50 split Genmab wants is a significant hurdle for partnerships with big pharma i believe. and very possibly one of the reasons some of the larger bi-specific deals we have seen over the last few months were not with genmab technology. But i can't blame them for pursuing 50/50, after what happened with JNJ, i would also not want to be in a position like that again...
	5/2 17:52 af JørgenVarnæs	var det ikke Novod, der kaldte set-uppet for "døde penge"
	5/2 17:50 af JørgenVarnæs	Masser af R, begrænset D og tungetunge administrationsomkostninger
	5/2 17:48 af Solsen	Vilje til udvikling ? Kig på R&D omkostningerne.
	5/2 17:47 af Solsen	Vi er nok alle irriteret over kursen ikke er over 3000. Aktiekursen har sit eget liv, som JW siger. Vi kan ikke pege på en præcis årsag til at kursen roder rundt hernede. I min optik er kursen for lav. Men hvornår det bliver bedre vil jeg ikke gætte på.
	5/2 17:47 af JørgenVarnæs	tilsammen har de 2 en krigskasse, der kan løfte lidt af hvert. Ikke siden zalutumumab har GEN lagt "dollars to donuts" - og jeg har savnet vilje til udvikling fra GENs side
	5/2 17:44 af Sukkeralf	Håber at de får en stor spiller, hvis de har endnu et guldkorn i pipelinen. Synes stadig ikke de har erfaring nok til at løfte et kæmpe klinisk projekt alene eller sammen med BioNTech.
	5/2 17:43 af Solsen	Du skal ikke være ked af det Raun. Det er jo ikke et personligt angreb.
	5/2 17:43 af JørgenVarnæs	mon ikke Jan er blevet lidt håndsky efter tabet af faspro? Den slags løfter kan nemt medføre sagsanlæg
	5/2 17:42 af Sukkeralf	Jan blev på JP Morgan spurgt ind til om udviklingen i Genmab var afhængig af om Janssen tog optionen på hexCD38 - en gang udenomssnak gav det indtryk, at Genmab havde nok pipelineprojekter uden Janssen.
	5/2 17:34 af Raun	@Solsen .... Er vitterlig ked af at du har fået den opfattelse at jeg skulle være mega negativ på aktien, hvilket jeg heller ikke kan forstå
	5/2 17:33 af JørgenVarnæs	Interesting EL - still some life in the mab's / tabart development sphere
	5/2 17:30 af JørgenVarnæs	Jamen, så ligger løsningen jo ligefor Solsen
	5/2 17:28 af E L	Novartis (NVS) in Advanced Talks to Acquire -our old patent infringement lawsuit friend- Morphosys (MOR) - Reuters
	5/2 17:28 af Solsen	Jeg gider ikke tage en diskussion op for det er håbløst. Men hvis man konstant er mega negativ så burde man ikke eje aktien.